noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 13, 1995.

A. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. The Berens Corporation, Houston, Texas; To engage *de novo* through its subsidiary, Berens Credit Corporation, Houston, Texas, in making and arranging loans and other extensions of credit, pursuant to § 225.25(b)(1); and leasing activities, pursuant to § 225.25(b)(5) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, May 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–13211 Filed 5–30–95; 8:45 am]

BILLING CODE 6210–01–F

Societe Generale; Notice To Engage in Nonbanking Activities

Societe Generale, Paris, France (Notificant), has provided notice pursuant to section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) (BHC Act) and § 225.23(a)(3) of the Board's Regulation Y (12 CFR 225.23(a)(3)), to acquire through its subsidiary, FIMAT Futures USA, Inc., Chicago, Illinois (Company), substantially all of the assets of Brody, White & Company, Inc., New York, New York (Brody White). Company currently engages in a variety of futures commission merchant and foreign exchange-related activities. *See Societe Generale*, 80 Federal Reserve Bulletin 649 (1994) (Societe Generale I) and *Societe Generale*, 80 Federal Reserve Bulletin 646 (1994) (Societe Generale II). Upon acquisition of Brody White, Company would expand its activities to include becoming a clearing member of the New York Cotton Exchange, Commodity Exchange, Inc., Financial Exchange, New York Futures Exchange and the Coffee, Sugar & Cocoa Exchange; purchasing and selling through omnibus accounts futures and options on futures on the London Commodity Exchange and Winnipeg Commodity Exchange; and acting as riskless principal in connection with spot, forward and over-the-counter option transactions in the foreign exchange market.

Notificant has stated that upon acquisition of Brody White, Company would continue to provide futures commission merchant execution, clearance and advisory services subject to the same limitations, conditions and commitments relied on by the Board in Societe Generale I, with one exception. In particular, Notificant proposes that Company provide execution, clearance and advisory services to commercial hedger customers with net worths of less than $1 million. The Board previously has relied on commitments that clearing-only services and futures commission merchant services provided with respect to futures and options on futures on nonfinancial commodities would be provided solely to institutional customers, as defined in § 225.2(g) of Regulation Y. Notificant has represented that these customers would not be unsophisticated retail investors. Notificant also has stated that in order to address suitability and credit risk issues, as well as any other possible adverse effects, noninstitutional customers would have to represent in writing that they are engaged in bona fide hedging transactions for purposes of CFTC regulation 1.3(z) (17 CFR 1.3(z)), and Company would have a system in place to detect any unauthorized trading by these customers in commodities other than those as to which hedge margin status has been granted. In addition, there would be an initial credit review process to determine whether a customer's proposed hedging activities are appropriate in light of the customer's net worth and business activities, as well as periodic reviews on actual trading activities in the account. Based on these facts, Notificant maintains that providing the proposed futures commission merchant services to certain noninstitutional customers is so closely related to banking as to be a proper incident thereto.

Notificant also has stated that upon acquisition of Brody White, Company would purchase and sell, on the order of investors as riskless principal, foreign exchange in the spot, forward and over-the-counter option markets. Notificant maintains that the Board previously has determined that purchasing and selling foreign exchange as riskless principal is closely related to banking. *See Banca Commerciale Italiana*, 76 Federal Reserve Bulletin 649 (1990) (BCI). Notificant has stated that Company would provide the proposed riskless principal services in accordance with the limitations, commitments and conditions relied on by the Board in BCI. Notificant also has stated that Company would continue to comply with commitments made to the Board in Societe Generale II that relate to providing foreign exchange execution and advisory services on a combined basis.

In order to approve the proposal, the Board must determine that the proposed activities to be conducted by Company ''can reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' 12 U.S.C. 1843(c)(8). Notificant maintains that the proposal would not produce any adverse effects. Notificant also maintains that the proposal would lead to increased competition in the relevant markets, better customer service, lower costs and greater efficiency.

Any comments or requests for hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, D.C. 20551, not later than June 30, 1995. Any request for a hearing on this notice must, as required by § 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(e)), be accompanied by a statement of the reasons why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

This notice may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve System, May 24, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–13212 Filed 5–30–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Advisory Committee on Immunization Practices (ACIP).

Times and Dates: 8:30 a.m.–6 p.m., June 28, 1995; 8:15 a.m.–3:30 p.m., June 29, 1995.

Place: CDC, Auditorium A, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents.

Matters to be discussed: The committee will discuss the polio vaccine policy; the approach to developing ACIP vaccine recommendations; hepatitis A vaccine—use in high endemic populations; varicella update; ''Vaccines for Children Program'': Hepatitis A, hepatitis B, varicella; adolescent immunization visit; measles elimination update; vaccine safety update: preference of DTaP for 4th and 5th doses; ACIP participation in the National Vaccine Advisory Committee and the Advisory Commission on Childhood Vaccines Subcommittee on Vaccine Safety; measles vaccine inflammatory bowel disease; large-linked database (LLDB) results; acellular pertussis vaccine trial results; programmatic strategies to increase immunization coverage; pneumococcal conjugate vaccine; harmonization of immunization recommendations; update on progress towards disease elimination goals; ACIP recommendations and package inserts; diphtheria and the New Independent States update: the U.S. contingency plan; electronic updating of ACIP recommendations; an Injury Compensation Program update; and a National Vaccine Program update. Other matters of relevance among the committee's objectives may be discussed.

Agenda items are subject to change as priorities dictate.

Contact person for more information: Gloria A. Kovach, Committee Management Specialist, CDC (1–B72), 1600 Clifton Road, NE, Mailstop A20, Atlanta, Georgia 30333, telephone 404/639–3851.

Dated: May 24, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–13209 Filed 5–30–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0097]

New Monographs and Revisions of Certain Food Chemicals Codex Monographs; Opportunity for Public Comment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on pending changes to certain Food Chemicals Codex specifications monographs from the third edition and its four supplements. One new monograph and additions, revisions, and corrections to current monographs for certain substances used as food ingredients are being prepared by the National Academy of Sciences/Institute of Medicine (NAS/IOM) Committee on Food Chemicals Codex (the committee). This material will be published in the fourth edition of the Food Chemicals Codex, which is scheduled for release in March 1996. When the committee completes its review of the comments, it will incorporate any changes that it makes in response to comments in monographs published in supplements to the fourth edition.

DATES: Written comments by August 14, 1995.

ADDRESSES: Submit written comments and supporting data and documentation to the NAS/IOM Committee on Food Chemicals Codex, National Academy of Sciences, 2101 Constitution Ave., NW., Washington, DC 20418. Copies of the new monographs and proposed revisions to current monographs may be obtained from NAS (address above) or the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Requests for copies should specify the monographs desired.

FOR FURTHER INFORMATION CONTACT:

Fatima N. Johnson, Committee on Food Chemicals Codex, Food and Nutrition Board, National Academy of Sciences, 2101 Constitution Ave., NW., Washington, DC 20418, 202–334–2580; or

Paul M. Kuznesof, Center for Food Safety and Applied Nutrition (HFS–247), Food and Drug Administration, 200 C Street, SW., Washington, DC 20204, 202–418–3009.

SUPPLEMENTARY INFORMATION: By contract with NAS/IOM, FDA supports the preparation of the Food Chemicals Codex, which is a compendium of specifications for substances used as food ingredients. Before any specifications are included in a Food Chemicals Codex publication, public announcement is made in the **Federal Register**.

FDA previously announced that the committee was considering new monographs and monograph revisions for inclusion in the fourth edition of the Food Chemicals Codex, which NAS/IOM is now preparing. In addition, FDA has given notice and an opportunity for public comment on the policies adopted by the committee for the fourth edition on lead and heavy metals specifications (58 FR 38129, July 15, 1993), and on arsenic specifications (59 FR 11789, March 14, 1994).

The committee will continue to provide the opportunity for public comment on intended changes in monographs by means of **Federal Register** notices before their inclusion in supplements to the fourth edition. Interested parties should submit all suggestions with supporting documentation to the National Academy of Sciences at the above address.

FDA now gives notice that the committee is soliciting comments and information on certain proposed new monographs and revisions to certain additional current monographs. These new monographs and revisions will be published in the fourth edition of the Food Chemicals Codex. The proposed new monographs and revisions to current monographs may be seen at the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. Because the publication timeframe for the fourth edition, comments on monographs that are the subject of this notice cannot be considered for incorporation in the fourth edition, which is scheduled for release in March 1996, but will be considered for incorporation in supplements to the fourth edition. Copies of the new monographs and proposed revisions to current monographs may be obtained from NAS or the Dockets Management Branch. Requests for copies should be identified with the docket number found in brackets in the heading of this